Martín-Carbonero L, Sánchez-Somolinos M, García-Samaniego J, Núñez M J, Valencia M E, González-Lahoz J, Soriano V
Service of Infectious Diseases and Hepatology Unit, Hospital Carlos III, Madrid, Spain.
J Viral Hepat. 2006 Dec;13(12):851-7. doi: 10.1111/j.1365-2893.2006.00778.x.
Since the advent of highly active antiretroviral therapy (HAART), complications of chronic liver disease (CLD) have emerged as one of the leading causes of hospital admission and death among HIV-infected patients with chronic hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infections. The impact of CLD on hospital admissions and deaths in HIV-infected patients attended at one reference HIV hospital in Madrid during the last 9 years was analysed. All clinical charts from January 1996 to December 2004 were retrospectively examined. Demographics, discharge diagnosis, complications during inhospital stay and causes of death were recorded. A total of 2527 hospital admissions in 2008 distinct HIV-infected persons were recorded. Overall, 84% were iv drug users; mean age was 37 years and the mean CD4 count was 224 cells/muL. Both mean age and CD4 count significantly increased during the study period (P < 0.01). Overall, 42% of hospitalized patients were on antiretroviral therapy. Decompensated CLD was the cause of admission and/or developed during hospitalization in 345 patients (14%). Admissions caused by decompensated CLD increased significantly from 9.1% (30/329) in 1996 to 26% (78/294) in 2002. A significant steady decline occurred since then, being 11% (29/253) in the year 2004. Similarly, inhospital liver-related deaths were 9% (5/54) in 1996, peaked to 59% (10/17) in 2001 and declined to 20% (3/15) in the year 2004. Chronic hepatitis C was responsible for admissions and/or deaths in 73.5% of CLD cases. In conclusion, the rate of liver-related hospital admissions and deaths among HIV-infected patients peaked in the year 2002 and has steadily declined since then. A slower progression to liver cirrhosis in patients on HAART, avoidance of hepatotoxic antiretroviral drugs and more frequent use of anti-HCV therapy in HIV/HCV-coinfected patients could account for this benefit.
自从高效抗逆转录病毒治疗(HAART)出现以来,慢性肝病(CLD)并发症已成为感染慢性乙型肝炎病毒(HBV)和/或丙型肝炎病毒(HCV)的HIV感染者住院和死亡的主要原因之一。分析了过去9年中马德里一家参考HIV医院收治的HIV感染者中CLD对住院和死亡的影响。回顾性检查了1996年1月至2004年12月的所有临床病历。记录了人口统计学资料、出院诊断、住院期间的并发症和死亡原因。共记录了2008名不同HIV感染者的2527次住院情况。总体而言,84%为静脉吸毒者;平均年龄为37岁,平均CD4细胞计数为224个/微升。在研究期间,平均年龄和CD4细胞计数均显著增加(P<0.01)。总体而言,42%的住院患者正在接受抗逆转录病毒治疗。失代偿性CLD是345例患者(14%)的入院原因和/或在住院期间发生。失代偿性CLD导致的入院率从1996年的9.1%(30/329)显著增加到2002年的26%(78/294)。从那时起出现了显著的稳步下降,2004年为11%(29/253)。同样,1996年与肝脏相关的住院死亡率为9%(5/54),2001年达到峰值59%(10/17),2004年降至20%(3/15)。慢性丙型肝炎在73.5%的CLD病例中导致入院和/或死亡。总之,HIV感染者中与肝脏相关的住院率和死亡率在2002年达到峰值,此后稳步下降。接受HAART治疗的患者向肝硬化进展较慢、避免使用具有肝毒性的抗逆转录病毒药物以及在HIV/HCV合并感染患者中更频繁地使用抗HCV治疗可能是造成这种情况的原因。